Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.
Press releases published on May 13, 2025
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
May 13, 2025
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene …
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
GlobeNewswire
·
May 13, 2025
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo- …
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 13, 2025
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with …
Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025
GlobeNewswire
·
May 13, 2025
LENMELDY™ is the first and only disease-modifying intravenous infusion proven to extend life expectancy in pre-symptomatic late infantile (PSLI) patients and mitigate the cognitive and/or physical impact of early-onset MLD Six accepted abstracts at ASGCT …
Immatics Announces First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
May 13, 2025
IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026 IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic …
Farmers of Salem Proudly Spotlights Breast Cancer Survivor and Employee, Loraine Lester, for Her Generous Charitable Giving Work
GlobeNewswire
·
May 13, 2025
WILMINGTON, Del., May 13, 2025 (GLOBE NEWSWIRE) -- Farmers of Salem, a regional mutual insurance company specializing in insurance for home and business owners, is proud to support employee involvement in charitable activities that improve the quality of …
EyePoint Announces Participation at Upcoming Investor Conferences
GlobeNewswire
·
May 13, 2025
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
GlobeNewswire
·
May 13, 2025
FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate …
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
GlobeNewswire
·
May 13, 2025
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 million Over 6,000 patients treated to date Initiated CARVYKTI® clinical production at the Tech Lane facility Received positive CHMP opinion to add statistically …
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025
GlobeNewswire
·
May 13, 2025
REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data on the burden …
Axovia Therapeutics Presents New Preclinical Data for AXV-101 for the Treatment of Blindness Associated with BBS Mutations at ASGCT
GlobeNewswire
·
May 13, 2025
- Data support planned dosing regimen and protocol for FIH study to initiate in mid-2025 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity …
Altimmune Announces First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
May 13, 2025
Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, …
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
GlobeNewswire
·
May 13, 2025
VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce …
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
GlobeNewswire
·
May 13, 2025
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which …
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
GlobeNewswire
·
May 13, 2025
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has …
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 13, 2025
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, …
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
GlobeNewswire
·
May 13, 2025
Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high productivity, suspension-based manufacturing …
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 13, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its …
Microbix & Aurevia Introduce Novel EQA Scheme
GlobeNewswire
·
May 13, 2025
MISSISSAUGA, Ontario and HELSINKI, Finland, May 13, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Aurevia Oy via its Labquality EQAS affiliate (Aurevia), …
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GlobeNewswire
·
May 13, 2025
GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into …